The following information is obtained from various newswires,
published medical journal articles, and medical conference presentations.
Company: Genentech
Approval Status: Approved October 1998
Treatment for: Breast cancer
General Information
Herceptin (trastuzumab) is used as a second- or third-line therapy for patients with metastatic breast cancer.